Table 1. Baseline characteristics of HIV-positive women by HCV statusa.
| HCV antibody negative (n=1,734) |
Cleared HCVb (n=231) |
Chronic HCVb (n=751) |
|
|---|---|---|---|
| Demographic characteristics | |||
| Agec,d,e | 34 (8) | 39 (8) | 40 (6) |
| Race/ethnicity | |||
| African Americanc,d,e | 941 (54%) | 104 (45%) | 470 (63%) |
| Hispanicd,e | 489 (28%) | 68 (29%) | 144 (19%) |
| Whitec,e | 235 (14%) | 52 (23%) | 124 (17%) |
| Other | 69 (4%) | 7 (3%) | 13 (2%) |
| Education | |||
| < High schoold | 603 (35%) | 93 (40%) | 331 (44%) |
| High school | 512 (30%) | 65 (28%) | 242 (32%) |
| > High schoold,e | 613 (35%) | 73 (32%) | 178 (24%) |
| Unknown | 6 (0%) | 0 | 0 |
| Household income | |||
| ≤ $12,000c,d | 903 (52%) | 156 (68%) | 533 (71%) |
| $12,001- $30,000c,d | 508 (29%) | 50 (22%) | 155 (21%) |
| > $30,000c,d | 274 (16%) | 20 (9%) | 38 (5%) |
| Unknown | 49 (3%) | 5 (2%) | 25 (3%) |
| Smoking | |||
| Neverc,d,e | 794 (46%) | 32 (14%) | 67 (9%) |
| Former c,d,e | 647 (37%) | 145 (63%) | 584 (78%) |
| Current c,d,e | 293 (17%) | 54 (23%) | 100 (13%) |
| Ever injection drug usec,d | 56 (3%) | 183 (79%) | 632 (84%) |
| Enrollment periodc,d | |||
| 1994-1995 | 1111 (64%) | 202 (87%) | 682 (91%) |
| 2001-2002 | 623 (36%) | 29 (13%) | 69 (9%) |
| HIV disease characteristics | |||
| HAART naïvec,d | 1310 (76%) | 215 (93%) | 710 (95%) |
| Log10 HIV copies/mLd,e | 3.9 (1.2) | 3.9 (1.2) | 4.2 (1.1) |
| CD4+ cells/mLd,e | 420 (293) | 458 (349) | 384 (294) |
| CD4/CD8 ratiod | 0.54 (0.43) | 0.52 (0.38) | 0.47 (0.36) |
a
Continuous variables expressed as mean (standard deviation). Differences assessed by Fisher's exact test (categorical variables) or Mann-Whitney test (continuous variables). Race/ethnicity was by self-report.
b
Women with “HCV clearance” were HCV antibody positive and HCV RNA negative at enrollment (n=204) or HCV RNA positive at enrollment but HCV RNA negative on a follow-up HCV RNA test (n=27). Women with “chronic HCV” were persistently positive at every available HCV RNA test. The “cleared HCV” and “chronic HCV” groups were exclusive (no overlap over time).
c
P<0.05 between HCV antibody negatives vs. women with cleared HCV
d
P<0.05 between HCV antibody negatives vs. women with chronic HCV
e
P<0.05 between women with cleared vs. chronic HCV